Melanotan II

What Melanotan II is

Melanotan II (MT-II) is a synthetic cyclic lactam heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide derived from proopiomelanocortin (POMC) ^[1]. It was developed in the late 1980s by Hadley, Hruby, and colleagues at the University of Arizona as part of a structured program in structure-activity relationship research on α-MSH analogs, with the primary objective of producing a potent, metabolically stable agonist of the melanocortin receptor family suitable for investigation of pigmentation biology, central energy regulation, and melanocortin pharmacology ^[2]. Researchers sought to improve upon the rapid enzymatic breakdown of native α-MSH by creating a shorter, cyclized structure; the result was a compound substantially more resistant to proteolytic degradation and with a broader receptor binding profile than its linear precursor ^[3].

Unlike the related peptide melanotan I (afamelanotide), which was subsequently developed into an approved pharmaceutical for erythropoietic protoporphyria, Melanotan II was never successfully advanced to regulatory approval ^[4]. Its chemical formula is Ac-Nle-cyclo(Asp-His-D-Phe-Arg-Trp-Lys)-NH2, giving it a cyclic lactam bridge that confers structural rigidity and prolonged receptor engagement ^[5]. As a non-selective pan-melanocortin agonist, it interacts with MC1R (pigmentation), MC3R and MC4R (appetite and sexual function), and MC5R, producing multiple simultaneous biological effects in experimental models ^[6]. The foundational characterization of the compound's design rationale was published by Al-Obeidi, Castrucci, Hadley, and Hruby in the Journal of Medicinal Chemistry in 1989 ^[2].

What it is being researched for

1. Skin Pigmentation and Melanogenesis

The most extensively studied property of MT-II in early research is its capacity to stimulate melanin production without UV light exposure. By activating MC1R on epidermal melanocytes, the compound triggers the cAMP-PKA signaling cascade, upregulating the enzyme tyrosinase and driving preferential synthesis of eumelanin (brown-black pigment) over phaeomelanin (yellow-red pigment) ^[7]. A 1996 pilot Phase I human study by Dorr and colleagues — considered the foundational human trial — confirmed that a short series of subcutaneous administrations produced measurable, visible skin tanning in healthy male volunteers within days, accompanied by quantitative reflectance changes ^[3]. Subsequent preformulation and pharmacological work positioned MT-II as a potential chemoprevention tool for sunlight-induced skin cancers by providing baseline pigmentary photoprotection ^[8]. However, the compound carries concurrent safety signals in melanocytic tissue (see Evidence section), which substantially limits its translational trajectory in this area ^[9].

2. Sexual Dysfunction Research

MT-II's potential to influence sexual function was an unanticipated finding that emerged during the compound's early development as a tanning agent; a researcher self-administering the peptide experienced a prolonged erection as an adverse effect, which redirected a portion of subsequent research toward this indication ^[4]. Formal investigation followed: a double-blind, placebo-controlled crossover study by Wessells and colleagues in ten men with psychogenic erectile dysfunction found that clinically apparent erections developed in eight of ten participants treated with MT-II, compared to none in the placebo arm, with a statistically significant difference in duration of rigidity ^[10]. Further work by Wessells, Levine, Hadley, and colleagues documented increases in both penile rigidity and reported sexual desire in men with organic erectile dysfunction ^[11]. Published reviews of melanocortin receptor agonists note that MT-II has also been studied in female sexual arousal disorder models, though evidence in women remains limited ^[4]. The sexual function lineage ultimately led to the development of bremelanotide (PT-141), a carboxylate derivative of MT-II that advanced to Phase II human trials ^[12].

3. Appetite Regulation and Energy Balance

Melanotan II has been widely used as a tool compound in preclinical investigations of feeding behavior and energy homeostasis because of its potent activation of MC4R, the melanocortin receptor subtype identified as a key central regulator of food intake ^[6]. Animal studies demonstrated that central or peripheral administration of MT-II produced pronounced appetite suppression, weight loss, and increased energy expenditure, effects that were blocked by the melanocortin antagonist SHU9119, confirming on-target activity ^[13]. Critically, MC4R-knockout mice were resistant to the appetite-reducing effects of MT-II, while wild-type littermates responded normally, establishing MC4R as the primary receptor mediating these feeding-related outcomes ^[13]. MT-II also reduced the orexigenic and adipogenic effects of neuropeptide Y (NPY) in rat models, curtailing NPY-driven increases in fat pad weight and insulin secretion ^[14]. A 2022 study in the nucleus accumbens of mice extended this picture, demonstrating that local MT-II application decreased both appetitive motivation and consumptive food responding, implicating MC3R and MC4R in reward-related feeding circuits beyond the hypothalamus ^[15].

4. Thermogenesis and Brown Adipose Tissue

A separate line of preclinical research has examined MT-II's influence on adaptive thermogenesis, particularly in the context of brown adipose tissue (BAT) function. A 2021 study published in Experimental Physiology by McMillan, Forster, and colleagues at the University of Northern British Columbia used a genetic model of pituitary adenylate cyclase-activating polypeptide (PACAP) deficiency to show that treatment with the melanocortin agonist MT-II could partially rescue impaired thermogenic capacity during cold acclimation ^[16]. These findings provided evidence that PACAP acts upstream of the melanocortin system in regulating sympathetic nerve activity to BAT in mice, positioning MT-II as a useful probe for dissecting the neuroendocrine architecture of energy expenditure. Research using MC4R-specific tools has further shown that activation of MC4Rs in the brainstem can independently suppress food intake and stimulate energy expenditure, suggesting that deep brain penetration may not be required for melanocortin-driven thermogenic effects ^[17].

5. Melanoma Biology: Dual Research Questions

MT-II sits at a complex intersection in melanoma research: it has been investigated both as a potential melanocyte stimulant that could theoretically promote malignant transformation and, paradoxically, as a possible anti-tumor agent. On the precautionary side, published case reports have linked MT-II use to eruptive dysplastic nevi, rapid darkening of existing lesions, and coincident melanoma diagnoses, most notably a 2014 report in Dermatology by Hjuler and colleagues documenting a melanoma in a 20-year-old woman who had self-administered MT-II in conjunction with sunbed use ^[9]. A 2013 scientific review found no conclusive evidence of a direct causal relationship, and a 2021 review concluded that increased UV-seeking behavior among MT-II users may account for the observed melanoma association ^[18]. Conversely, a 2020 in vivo study published in PMC (NCT-based experimental work using the B16-F10 model) found that topical MT-II application significantly attenuated tumor progression, inhibited melanoma cell migration and invasion, and induced apoptosis in established melanoma — raising questions about context-dependent effects on melanocytic biology ^[19].

6. Oral Mucosal Pigmentation

A growing body of case-level evidence has documented pigmentary changes in oral mucosal tissue following MT-II use, reflecting the presence of MC1R-expressing melanocytes in non-cutaneous tissues. A 2025 case report published in PMC described measurable intraoral pigmentation changes in a patient who self-administered MT-II over a 64-day period, with a three-month follow-up capturing the timeline of pigment development ^[5]. The report noted that Melanotan II may influence oral mucosal pigmentation through stimulation of MC1R on oral melanocytes, and referenced a separate case of intraoral melanoma potentially linked to nasal-spray administration of the compound ^[5]. These findings expand the research scope of MT-II beyond skin, underscoring the broad tissue distribution of melanocortin receptors.

7. Cardiovascular and Inflammatory Signaling

Although less prominent than its pigmentation and sexual function research profiles, MT-II has been noted in the broader melanocortin literature as a tool for studying cardiovascular and inflammatory pathways, consistent with the known physiological roles of endogenous melanocortin peptides ^[4]. Brainstem-targeted administration of MT-II in rodent studies has been shown to increase heart rate alongside reductions in food intake, suggesting that MC4R activation at brainstem level simultaneously affects autonomic cardiovascular control and energy regulation ^[17]. Published reviews of the melanocortin system classify natural melanocortin hormones — and by extension, MT-II as their synthetic agonist — as involved in the immune system, inflammation, and the cardiovascular system, though the direct clinical relevance of MT-II's cardiovascular effects remains an area requiring further controlled investigation ^[4].

How it is thought to work

Melanotan II functions as a non-selective, pan-melanocortin receptor agonist, meaning it binds to and activates multiple subtypes within the five-member melanocortin receptor family: MC1R, MC3R, MC4R, and MC5R ^[6]. Each receptor subtype is a G-protein-coupled receptor (GPCR) with distinct tissue expression and physiological roles; native α-MSH shows preferential activity at MC1R on melanocytes, but MT-II's cyclic structure and modified amino acid composition give it high affinity across the family ^[7]. For its pigmentation effects, the primary mechanism is activation of MC1R on melanocytes, which triggers adenylyl cyclase, elevates intracellular cyclic AMP (cAMP), and activates protein kinase A (PKA). PKA phosphorylation cascades upregulate MITF (microphthalmia-associated transcription factor) and the enzyme tyrosinase, shifting melanin synthesis from phaeomelanin toward eumelanin, resulting in darkened pigmentation independent of UV light ^[7][8].

For its central nervous system effects on appetite and sexual function, MT-II crosses into hypothalamic and other brain regions where MC3R and MC4R are concentrated, particularly in the paraventricular nucleus and arcuate nucleus ^[6]. Activation of MC4R in these areas stimulates adenylyl cyclase and generates anorexigenic (appetite-suppressing) signaling cascades, counteracting the orexigenic tone maintained by neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons ^[14]. The appetite-suppressing effect is absent in MC4R-knockout animals, which are resistant to MT-II's anorectic properties, confirming that this receptor is the primary mediator ^[13]. For sexual function effects, activation of melanocortin receptors in the brain is thought to provide a centrally mediated, non-vascular pathway to arousal and erection — distinct from the peripheral vascular mechanism targeted by phosphodiesterase-5 inhibitors ^[12]. The compound's non-selectivity is a key pharmacological caveat: researchers studying any single downstream effect must control for concurrent receptor engagement across the whole melanocortin family ^[6].

Where the evidence stands

The human evidence base for Melanotan II is thin and limited to early-phase, small-sample trials. The foundational 1996 Phase I pilot study by Dorr and colleagues in Life Sciences enrolled only three healthy male volunteers and confirmed dose-dependent skin tanning, but also documented nausea, flushing, and spontaneous penile erections as primary adverse effects ^[3]. A double-blind, placebo-controlled crossover study by Wessells and colleagues in ten men with psychogenic erectile dysfunction found statistically significant erectogenic effects, with eight of ten participants developing clinically apparent erections ^[10]. A subsequent study by Wessells, Levine, Hadley, and colleagues in men with organic erectile dysfunction corroborated increases in penile rigidity and sexual desire ^[11]. As of late 2026, no Phase III human safety or efficacy trial for MT-II has been published, and the compound has not received regulatory approval in any jurisdiction ^[18]. A Phase II randomized trial examining MT-II as an adjunct to narrowband UVB phototherapy for stable nonsegmental vitiligo is listed on ClinicalTrials.gov, representing one of the more recent formal human research efforts ^[20].

The preclinical evidence base is considerably richer. Rodent and cell studies have consistently demonstrated appetite suppression, thermogenic modulation, and receptor-specific signaling outcomes, with mechanistic findings replicated across multiple independent laboratories ^{[13][14][15][16]}. A 2020 in vivo study found MT-II suppressed established melanoma tumor progression in the B16-F10 mouse model ^[19], while published case reports in human subjects document eruptive nevi, rapid mole changes, and coincident melanoma diagnoses — a potential safety signal that has not been resolved by controlled study ^[9][18]. Whether the melanoma associations represent a pharmacological effect of MT-II or a confounding behavior (increased UV seeking and sunbed use) remains scientifically contested; a 2021 review leaned toward the UV exposure explanation, while acknowledging the mechanistic plausibility of melanocyte over-stimulation as a contributing factor ^[18]. Overall, the evidence gap between preclinical promise and human safety characterization is the defining limitation of the MT-II research literature.

Frequently asked questions

What is Melanotan II and how is it different from Melanotan I?

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona. Melanotan I (afamelanotide) is a related linear analog that was subsequently approved in some countries as a pharmaceutical for erythropoietic protoporphyria. Melanotan II has a shorter, cyclized structure that gives it broader, non-selective activity across multiple melanocortin receptor subtypes (MC1R, MC3R, MC4R, MC5R), while Melanotan I is more selective. Unlike Melanotan I, Melanotan II has not achieved regulatory approval anywhere.

What receptors does Melanotan II act on?

Melanotan II is a non-selective pan-melanocortin receptor agonist with activity at MC1R, MC3R, MC4R, and MC5R. MC1R activation on melanocytes drives skin pigmentation by upregulating eumelanin production. MC3R and MC4R activation in the brain and hypothalamus influences appetite suppression and sexual arousal signaling. Because it activates multiple receptor subtypes simultaneously, interpreting results from any single research endpoint requires careful experimental controls.

Has Melanotan II been tested in humans?

Yes, but only in small early-phase trials. The foundational human study was a 1996 Phase I pilot by Dorr and colleagues enrolling three volunteers, which confirmed skin tanning activity. A double-blind, placebo-controlled crossover study by Wessells and colleagues enrolled ten men with psychogenic erectile dysfunction and showed statistically significant erectogenic effects. No Phase III safety or efficacy trial has been published as of late 2026, and the compound is not an approved therapeutic.

What is the connection between Melanotan II and bremelanotide (PT-141)?

Bremelanotide (PT-141) is the carboxylate derivative of Melanotan II, developed specifically to pursue the sexual function indication that was unexpectedly discovered during MT-II's early development as a tanning agent. PT-141 advanced to Phase II human trials for sexual dysfunction and eventually received FDA approval under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women. MT-II itself was not developed further as a therapeutic.

Does Melanotan II cause cancer or melanoma?

This is scientifically unresolved. Published case reports have documented melanoma diagnoses in individuals who used MT-II, often in combination with heavy UV or sunbed exposure. A 2013 review found no conclusive evidence of direct causation, and a 2021 review attributed increased melanoma risk primarily to UV-seeking behavior among users. Conversely, a 2020 preclinical study found that topical MT-II suppressed melanoma tumor progression in a mouse model. Causal inference in either direction cannot be drawn from the current literature.

Is Melanotan II approved for use by Health Canada, the FDA, or the EMA?

No. Melanotan II is not approved as a therapeutic by Health Canada, the U.S. FDA, the European Medicines Agency, or any comparable national regulator. Multiple regulatory bodies have issued warnings against its uncontrolled use. It is available as a research chemical for laboratory use only, not for human consumption.

What are the most common adverse effects observed in MT-II research?

The most consistently documented adverse effects in early human studies include nausea, facial flushing, spontaneous penile erections (in males), stretching and yawning, and decreased appetite. Case reports have additionally documented changes in existing moles or nevi, eruptive formation of new nevi, and — in rarer published reports — serious events such as priapism, rhabdomyolysis, renal infarction, and posterior reversible encephalopathy syndrome. Long-term safety data from controlled trials does not exist.

How does Melanotan II produce skin tanning without sunlight?

MT-II activates MC1R receptors on melanocytes, which triggers a cAMP-PKA intracellular signaling cascade that upregulates the enzyme tyrosinase. Tyrosinase drives melanin synthesis and specifically shifts it toward eumelanin (brown-black pigment) rather than phaeomelanin (yellow-red pigment), producing visible skin darkening independent of UV radiation exposure. This is the same receptor pathway activated by natural α-MSH but achieved through a pharmacological agonist rather than sun exposure.

What role does Melanotan II play in appetite and obesity research?

MT-II is used as a tool compound in preclinical models to study the role of MC4R in appetite regulation and energy balance. Animal studies have shown that MT-II administration reduces food intake and body weight, an effect dependent on MC4R since knockout mice lacking the receptor are resistant to it. These preclinical findings have helped establish MC4R as a key target in obesity research, though MT-II itself has not been developed as an anti-obesity therapeutic.

Where can I find peer-reviewed research on Melanotan II?

Peer-reviewed research on MT-II is indexed primarily on PubMed and PubMed Central (PMC) at the National Library of Medicine (pubmed.ncbi.nlm.nih.gov). Key early papers include Dorr et al. (Life Sciences, 1996), Wessells et al. (Journal of Urology, 1998), and Hadley & Dorr (Peptides, 2006). Active clinical trials can be found on ClinicalTrials.gov. Researchers should consult primary literature directly and critically evaluate study size and design before drawing conclusions.

Glossary

α-Melanocyte-Stimulating Hormone (α-MSH)

An endogenous peptide hormone derived from proopiomelanocortin (POMC) that serves as the natural ligand for melanocortin receptors and regulates skin pigmentation, appetite, and other physiological processes.

Melanocortin Receptor (MCR)

A family of five G-protein-coupled receptors (MC1R–MC5R) that bind melanocortin peptides such as α-MSH and regulate diverse functions including pigmentation, energy balance, sexual function, inflammation, and immune responses.

Eumelanin

The brown-to-black form of melanin pigment produced preferentially when MC1R is activated on melanocytes, conferring a darker skin tone with greater UV-absorbing capacity than phaeomelanin.

Cyclic Lactam Peptide

A peptide in which the chain is cyclized by forming an amide (lactam) bond between a side-chain amine and a side-chain carboxylate, creating a ring structure that confers greater metabolic stability and conformational rigidity compared to linear peptides.

Non-Selective Agonist

A compound that activates multiple receptor subtypes within a family rather than binding to only one specific subtype, producing a broader range of simultaneous biological effects that can complicate interpretation of research outcomes.

Proopiomelanocortin (POMC)

A large precursor protein produced primarily in the pituitary gland and hypothalamus that is cleaved into multiple biologically active peptides including α-MSH, β-endorphin, and ACTH.

Bremelanotide (PT-141)

The carboxylate derivative of Melanotan II developed as a pharmaceutical; it received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women and is the most clinically advanced compound to emerge from MT-II research.

Eruptive Nevi

The sudden appearance of multiple new moles (melanocytic nevi) over a short time period, which has been documented as a safety signal in published case reports of individuals using Melanotan II.

References

1. Melanotan 2 and the Melanocortin Receptor Family: A Research Overview — Peptide Science Journal
2. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics. Journal of Medicinal Chemistry 32(12):2555–2561, 1989. — Journal of Medicinal Chemistry
3. Dorr RT et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777–84. — PubMed / Life Sciences
4. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006 Jan;27(4):921–30. — PubMed / Peptides
5. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. PMC 2025. — PubMed Central
6. Melanotan II — Overview (ScienceDirect Topics) — ScienceDirect / Elsevier
7. Melanotan II (MT-II): A Non-Selective Melanocortin Receptor Agonist Peptide — Mechanism and Safety — Superpower.com Research Guide
8. Dorr RT et al. Preformulation Studies with Melanotan-II: A Potential Skin Cancer Chemopreventive Peptide. Journal of Pharmaceutical Sciences. — ScienceDirect / Journal of Pharmaceutical Sciences
9. Hjuler KF et al. Melanoma Associated with the Use of Melanotan-II. Dermatology. 2014;228(1):34–36. PMID: 24355990. — PubMed / Dermatology (Karger)
10. Wessells H et al. Synthetic Melanotropic Peptide Initiates Erections in Men With Psychogenic Erectile Dysfunction: Double-Blind, Placebo Controlled Crossover Study. Journal of Urology. 1998;160:389–393. — ScienceDirect / Journal of Urology
11. Wessells H, Levine N, Hadley ME et al. Melanocortin Receptor Agonists, Penile Erection, and Sexual Motivation: Human Studies with Melanotan II. Int J Impot Res. 2000;12:S74–S79. — International Journal of Impotence Research
12. Melanocortin Receptors, Melanotropic Peptides and Penile Erection. PMC / Curr Top Med Chem. — PubMed Central
13. Raposinho PD et al. The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes in the male rat. J Neuroendocrinol. 2003;15(2):173–81. PMID: 12535159. — PubMed / Journal of Neuroendocrinology
14. Melanotan II Research: MC4R Activation, Hypothalamic Feeding Circuits, and Preclinical Energy Balance Findings — Core Research Peptides Research Blog (citing Marsh et al. 1999, Nat. Genet.)
15. Eliason NL et al. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022 Dec;96:102289. PMID: 36155088. — PubMed / Neuropeptides